Roche's star MS medicine Ocrevus wins EU approval
ZURICH (Reuters) - The European Union approved Roche's multiple sclerosis medicine Ocrevus, one the Swiss company's key new drugs that likely neared $1 billion in revenue in its first nine months on the U.S. market.
from Reuters: Health News http://reut.rs/2mrPELy
http://bit.ly/2zwRqiM